« Return to News | Awards & Advancement

Eli Lilly neuroscience chief steps down

Tuesday, March 1, 2011 08:52 AM

Faced with several clinical setbacks, Eli Lilly neuroscience chief David Bredt has left the company. Bredt joined Lilly in 2004, according to the Wall Street Journal.

The most notable of Lilly’s neurological drug setbacks was the Alzheimer's drug semagacestat, according to Fierce Biotech. The company halted further development of the drug in August 2010 after clinical trials revealed that semagacestat not only failed its endpoints on slowing progression, but also worsened the condition of the patients on the drug. More recently, an FDA panel rejected Lilly's Amyvid (florbetapir), an imaging chemical for Alzheimer's, saying Lilly needs to set up a training program to show physicians how to use the compound.

A spokesperson for Lilly told the WSJ that Bredt left voluntarily and that the company remains committed to neuroscience research. Almost a fifth of Lilly's pipeline drugs address neurological conditions, including late-stage compounds solanezumab for Alzheimer’s and Neri for depression.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.